Elimination of Viruses (Human Immunodeficiency, Hepatitis B, Vesicular Stomatitis and Sindbis Viruses) from an Intravenous Immunoglobulin Preparation

Vox Sanguinis ◽  
1987 ◽  
Vol 53 (2) ◽  
pp. 65-69 ◽  
Author(s):  
Yoshiaki Hamamoto ◽  
Shinji Harada ◽  
Naoki Yamamoto ◽  
Yahiro Uemura ◽  
Takashi Goto ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Preparation ◽  
Vesicular Stomatitis

Elimination of Viruses (Human Immunodeficiency, Hepatitis B, Vesicular Stomatitis and Sindbis Viruses) from an Intravenous Immunoglobulin Preparation

Vox Sanguinis ◽  
1987 ◽  
Vol 53 (2) ◽  
pp. 65-69 ◽  
Author(s):  
Yoshiaki Hamamoto ◽  
Shinji Harada ◽  
Naoki Yamamoto ◽  
Yahiro Uemura ◽  
Takashi Goto ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin Preparation ◽  
Vesicular Stomatitis

Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issue

2021 ◽  
Vol 51 (11) ◽  
pp. 1981-1982
Author(s):  
Karthik Nath ◽  
Thomas Wong ◽  
Ajit Ahluwalia ◽  
Scott Colquhoun ◽  
Paul J. Clark ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
Haematology Patients ◽  
Core Issue

Stability and Activity of Intravenous Immunoglobulin with Neonatal Dextrose and Total Parenteral Nutrient Solutions

1994 ◽  
Vol 28 (9) ◽  
pp. 1014-1017
Author(s):  
Christine A. Lindsay ◽  
Ken Dang ◽  
James M. Adams ◽  
Ching Nan Ou ◽  
Carol J. Baker
Keyword(s):  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
Surface Antigen ◽  
Immunoglobulin G ◽  
Functional Activity ◽  
Hepatitis B Surface Antigen ◽  
Type Iii ◽  
Apparent Decrease ◽  
Total Immunoglobulin

OBJECTIVE: To determine in vitro the compatibility of reconstituted intravenous immunoglobulin (IVIG) (Gammagard, Baxter-Hyland) with five different neonatal and pediatric intravenous solutions in Viaflex polyvinyl chloride bags. DESIGN: In vitro compatibility study. INTERVENTIONS: Samples were taken at time=0, 10, 30, 60, 90, and 120 minutes and at 4, 8, 12, and 24 hours and assayed for total immunoglobulin G content and antibodies to hepatitis B surface antigen. Type III group B Streptococcus (GBS) and opsonic activity for type III GBS were analyzed at time=0, 60, and 120 minutes and 12 and 24 hours. All results were compared with those from pure IVIG. RESULTS: Our results demonstrate that mixing IVIG with intravenous solutions commonly used in the care of premature infants (dextrose 5% in water [D5W], D15W, D5W/NaCl 0.225%, and total parenteral nutrition [TPN]) does not significantly alter total immunoglobulin G concentrations or concentration of antibodies to hepatitis B surface antigen or type III GBS. As well, the in vitro functional activity for type III GBS of the IVIG, when mixed with these solutions for up to 24 hours, remained intact. An apparent decrease in bactericidal killing was seen with the IVIG/central TPN mixture. This apparent decrease was found to be an artifact of the high concentration of glucose (20 percent) in the solution. CONCLUSIONS: We propose that Gammagard may be mixed with these solutions through Y-site connections without loss of antibody content or functional activity of the IVIG.

False positive hepatitis B virus core and surface antibodies due to intravenous immunoglobulin

2017 ◽  
Vol 47 (1) ◽  
pp. 119-120 ◽  
Author(s):  
Nicola Benwell ◽  
Peter Boan ◽  
Edward Raby ◽  
Ben McGettigan
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Intravenous Immunoglobulin ◽  
False Positive ◽  
Virus Core ◽  
B Virus ◽  
Surface Antibodies
Sign in / Sign up

Export Citation Format

Share Document